Francis J Giles Selected Research

Francis J Giles Research Topics

Disease

102	Neoplasms (Cancer) 01/2022 - 06/2002
52	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2016 - 06/2002
48	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 03/2002
33	Leukemia 10/2015 - 01/2002
27	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2015 - 06/2002
27	Hematologic Neoplasms (Hematological Malignancy) 09/2013 - 05/2002
18	Philadelphia Chromosome 01/2020 - 04/2002
14	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2017 - 08/2002
13	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2015 - 07/2002
10	Fatigue 01/2022 - 01/2003
7	Lymphoma (Lymphomas) 06/2019 - 12/2003
7	Multiple Myeloma 07/2012 - 05/2002
7	Pain (Aches) 09/2011 - 08/2002
6	Primary Myelofibrosis (Myelosclerosis) 08/2019 - 04/2003
6	Lung Neoplasms (Lung Cancer) 03/2018 - 03/2009
6	Diarrhea 11/2015 - 03/2003
6	Myeloid Leukemia (Leukemia, Myelocytic) 11/2010 - 06/2002
5	Nausea 01/2020 - 09/2003
5	Mucositis 12/2019 - 06/2002
5	Breast Neoplasms (Breast Cancer) 04/2018 - 02/2011
5	Acute Promyelocytic Leukemia 02/2013 - 06/2002
5	Thrombocytopenia (Thrombopenia) 05/2011 - 09/2002
5	Blast Crisis (Blast Phase) 03/2009 - 05/2002
4	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 12/2015
4	Melanoma (Melanoma, Malignant) 01/2021 - 12/2015
4	Prostatic Neoplasms (Prostate Cancer) 11/2019 - 09/2014
4	Neoplasm Metastasis (Metastasis) 01/2019 - 03/2012
4	Systemic Mastocytosis 11/2015 - 10/2006
4	Headache (Headaches) 11/2015 - 04/2003
4	Infections 08/2014 - 03/2003
4	Anemia 08/2014 - 04/2002
4	Exanthema (Rash) 10/2010 - 03/2003
4	Myeloproliferative Disorders (Myeloproliferative Disorder) 02/2008 - 04/2003
4	Pathologic Complete Response 06/2004 - 06/2002
4	Stomatitis 06/2004 - 08/2002
3	Carcinogenesis 12/2022 - 12/2003
3	Glioma (Gliomas) 01/2022 - 05/2016
3	Pancreatic Neoplasms (Pancreatic Cancer) 07/2021 - 06/2009
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 01/2016
3	Triple Negative Breast Neoplasms 04/2018 - 01/2014
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2016 - 01/2010

Drug/Important Bio-Agent (IBA)

27	Imatinib Mesylate (Gleevec)FDA Link 10/2015 - 05/2002
21	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2013 - 04/2002
20	Pharmaceutical PreparationsIBA 10/2021 - 04/2003
17	Proteins (Proteins, Gene)FDA Link 10/2021 - 07/2002
17	Phosphotransferases (Kinase)IBA 11/2019 - 07/2004
15	Tyrosine Kinase InhibitorsIBA 01/2020 - 09/2003
12	nilotinib FDA Link 01/2021 - 04/2009
11	Glycogen Synthase (Synthase I)IBA 12/2022 - 01/2017
11	Gemtuzumab (Mylotarg)FDA Link 05/2007 - 06/2002
10	Biomarkers (Surrogate Marker)IBA 01/2019 - 12/2003
10	NucleosidesIBA 01/2008 - 01/2002
10	fludarabineIBA 01/2008 - 04/2002
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2007 - 03/2002
9	Monoclonal AntibodiesIBA 01/2017 - 05/2002
9	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 02/2013 - 06/2002
9	bcr-abl Fusion ProteinsIBA 03/2011 - 07/2002
8	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2016
7	TOR Serine-Threonine KinasesIBA 04/2015 - 02/2004
7	Interferon-alpha (Interferon Alfa)IBA 04/2009 - 04/2002
7	troxacitabineIBA 01/2007 - 02/2002
6	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2022 - 05/2016
6	Messenger RNA (mRNA)IBA 01/2021 - 11/2003
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2011 - 08/2003
6	Everolimus FDA Link 08/2009 - 02/2004
5	Gemcitabine FDA Link 12/2019 - 08/2002
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2019 - 06/2002
5	AntigensIBA 01/2018 - 11/2003
5	Biological ProductsIBA 01/2015 - 01/2002
5	Vorinostat FDA Link 08/2014 - 07/2007
5	Daunorubicin (Cerubidine)FDA LinkGeneric 02/2013 - 05/2002
5	temsirolimus FDA Link 01/2010 - 02/2004
5	ridaforolimusIBA 08/2009 - 02/2004
5	Sirolimus (Rapamycin)FDA Link 08/2009 - 02/2004
5	Rituximab (Mabthera)FDA Link 04/2006 - 04/2003
4	AntibodiesIBA 01/2018 - 09/2004
4	DNA (Deoxyribonucleic Acid)IBA 11/2016 - 12/2003
4	EnzymesIBA 05/2015 - 11/2002
4	Histone Deacetylase InhibitorsIBA 08/2014 - 07/2007
4	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2008 - 08/2002
4	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 01/2008 - 08/2002
4	Decitabine FDA Link 12/2005 - 08/2003
4	Alemtuzumab (Campath)FDA Link 09/2004 - 05/2003
4	Topotecan (Hycamtin)FDA LinkGeneric 04/2004 - 06/2002
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 05/2002
3	Glycogen Synthase Kinase 3IBA 11/2019 - 01/2017
3	CytokinesIBA 08/2019 - 06/2002
3	LigandsIBA 06/2019 - 01/2008
3	Drug CombinationsIBA 01/2019 - 03/2012
3	HDL LipoproteinsIBA 02/2017 - 01/2015
3	ErbB Receptors (EGF Receptor)IBA 02/2017 - 01/2011
3	proto-oncogene proteins pimIBA 05/2016 - 02/2012
3	Sorafenib (BAY 43-9006)FDA Link 01/2016 - 09/2012
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2016 - 01/2011
3	Dasatinib (BMS 354825)FDA Link 07/2015 - 09/2008

Therapy/Procedure

106	Therapeutics 10/2021 - 01/2002
25	Drug Therapy (Chemotherapy) 12/2022 - 05/2002
14	Immunotherapy 01/2019 - 12/2015
5	Stem Cell Transplantation 01/2007 - 09/2002
3	Salvage Therapy 01/2016 - 04/2003